Clinical Trials Directory

Trials / Completed

CompletedNCT00447499

Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel

A Multi Center Open Label Study to Assess the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
59 (actual)
Sponsor
Ipsen · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine whether subjects with acromegaly (or their partners) are able to self administer Somatuline Autogel at home.

Detailed description

Clinical experience with Somatuline Autogel to date has raised the possibility of self or partner injection. Previous microparticle somatostatin analogue formulations required careful reconstitution and as a result the cost of the analogues and the inconvenience of reconstitution meant self or partner injection was not a viable option. Somatuline Autogel does not require reconstitution as it comes ready-mixed in a pre-filled syringe, thus making it more user-friendly than its predecessor and introducing the possibility of self or partner injection. Patients with acromegaly often travel considerable distances every 28 days in order to receive their somatostatin analogue injections in the clinic. If Somatuline Autogel can be safely administered unsupervised, while maintaining disease control, this could offer patients considerable benefits in terms of reduced frequency of visits to the clinic. This study is designed to allow suitably motivated patients with acromegaly or their partners to learn how to successfully inject Somatuline Autogel while maintaining their mean GH level control. Disease control in these patients will be assessed by comparing their GH and IGF-1 levels to accepted medical standards for control of acromegaly and by comparing the levels of GH and IGF-1 control achieved with baseline values.

Conditions

Interventions

TypeNameDescription
DRUGSomatuline Autogel (lanreotide acetate)Injections
BEHAVIORALHome administrationQuestionnaire

Timeline

Start date
2007-04-01
Primary completion
2008-12-01
Completion
2008-12-01
First posted
2007-03-14
Last updated
2020-11-20
Results posted
2010-12-20

Locations

13 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00447499. Inclusion in this directory is not an endorsement.